Drug Discovery & Development Virtual Event Series 2026

High-Quality GPCR Antibody Discovery Using Full-Length Nanodisc GPCR Proteins and Single B-Cell Technology

FEB 18, 2026 7:00 AM PST

Abstract

GPCRs represent one of the most important yet technically challenging classes of drug targets, largely due to difficulties in producing stable, native like antigens and generating high-quality antibodies. In this presentation, Dr. Donghui Ma will share DIMA Biotechnology’s integrated strategy for GPCR antibody discovery, combining proprietary full-length Nanodisc GPCR protein platforms with single B-cell cloning technology.

DIMA’s Nanodisc platforms enable the production of functional, full-length GPCR proteins that preserve native conformation and signaling activity. These proteins are used directly as antigens for antibody discovery, significantly improving antibody specificity, affinity, and functional relevance.

When paired with single B-cell technology, this approach allows rapid isolation of high quality monoclonal antibodies against challenging GPCR targets.

The presentation will highlight real-world case studies, key technical considerations, and data demonstrating how this workflow accelerates GPCR antibody generation with high success rates.

Attendees will gain practical insights into overcoming GPCR antibody discovery bottlenecks and enabling downstream applications in research, diagnostics, and drug development.

What You’ll Learn

01   Understand the key challenges in GPCR antigen preparation and antibody discovery and how Nanodisc-based full-length GPCR proteins address these limitations.

02  Evaluate the advantages of combining native-like GPCR antigens with single B-cell cloning for generating high-quality, functional antibodies.

03   Apply best practices and strategic considerations for accelerating GPCR antibody discovery with higher success rates and shorter timelines.

Technology Platforms Behind the Discovery

Nanodisc GPCR protein platforms

Single B-cell cloning technology

Featured Speaker

Donghui Ma, PhD

Dr. Donghui Ma is the Founder and CEO of DIMA Biotechnology, where he leads the development of integrated platforms for membrane protein production and antibody discovery. Prior to founding DIMA in 2019, Dr. Ma held senior leadership roles as General Manager and Chief Scientific Officer at biotechnology companies including OriGene, BioCheck, and Juventas, building deep expertise in antibody engineering and membrane protein science.

At DIMA, Dr. Ma has established proprietary Nanodisc platforms that enable the production of hundreds of functional full-length membrane proteins, covering a broad range of GPCR targets. These Nanodisc proteins maintain native conformation and activity and can be used as high-quality antigens for antibody generation. Using these validated antigens and a single B-cell antibody discovery platform, DIMA generated 5,000+ individual recombinant mAbs targeting 500+ drug targets, each supplied as a standalone, fully characterized antibody. By combining Nanodisc-based protein production with single B-cell antibody discovery, DIMA supports efficient and scalable biologics discovery for global biotechnology and pharmaceutical partners.

Who Should Attend

  • Antibody discovery scientists

  • GPCR drug discovery researchers

  • Structural biology teams working on membrane proteins

  • Biotech teams developing difficult therapeutic targets